Allergic Conjunctivitis Market Size & Share, by Drug Class (Antihistamines & Mast Cell Stabilizers, Corticosteroids); Disease Type, Distribution Channel - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2025-2037

Allergic Conjunctivitis Industry - Regional Synopsis

North America Market Analysis

North America is a key player in the allergic conjunctivitis market, projected to register a significant share of 53.1% in 2037. The dominance of the region is attributable to the increased burden of ocular diseases, their awareness, and the existing pharmaceutical base. This has encouraged the global players to launch more of such formulations. In July 2023, Harrow Inc. acquired the U.S. and Canada commercial rights to Santen’s branded ophthalmic products, including FLAREX, NATACYN, TOBRADEX ST, VERKAZIA, and ZERVIATE. The agreement also covers non-prescription brands FRESHKOTE and Cationorm PLUS. Hence, the move strengthens the company’s presence in the North America eyecare pharmaceutical market.

U.S. dominates the North America market owing to early adoption of cutting-edge treatment technologies. For instance, in February 2020, Alcon launched Pataday Once Daily Relief (olopatadine hydrochloride ophthalmic solution 0.2%) and Pataday Twice Daily Relief (olopatadine hydrochloride ophthalmic solution 0.1%) after receiving the U.S FDA clearance. These launches are to address the concerns of ocular diseases in the region and will amplify the market expansion during the forecast period. Additionally, the strong presence of global pharmaceutical leaders and an innovation-driven economy make the U.S. a hub for conjunctivitis advancements.

The Canada market is growing steadily with several collaborative approaches, including public-private partnerships, ensuring a robust treatment adoption across key sectors. In February 2024, Harrow Inc. and Apotex Inc. entered into an exclusive out-licensing agreement granting Apotex rights to market and distribute VERKAZIA for vernal keratoconjunctivitis, Cationorm PLUS to relieve dryness and irritation. Seek approval in Canada for VEVYE for dry eye disease, IHEEZO, and ZERVIATE for ocular itching due to allergic conjunctivitis. The deal aims to expand access to key ophthalmic treatments in the Canada market by leveraging their ecosystems and positioning Canada for global markets.

APAC Market Statistics

The Asia Pacific allergic conjunctivitis market is anticipated to grow at the fastest rate during the forecast period, driven by increasing instances of ocular allergies in the region. Governments in the region actively promote smart health campaigns, due to which the awareness increases, allowing substantial medical expenditure in the Asia Pacific. Moreover, countries such as China, India, and Japan are witnessing growing demand for eye care solutions as exposure to environmental pollutants and allergens intensifies densely populated areas placing Asia Pacific as key contributor for market progression.

China is a leader in the market, which is exceptionally supported by the increasing awareness of availing effective treatment for the disease. Moreover, the country’s supportive government, which emphasizes innovative management modalities, has fostered a favorable business environment for this sector. In September 2024, Nicox SA declared that its China-based partner, Ocumension Therapeutics, received approval for commercializing ZERVIATE (cetirizine ophthalmic solution) in China at a 0.24% concentration, for ocular itching, which is a symptom of allergic conjunctivitis. With these approvals, the country’s market continues to expand rapidly, shaping the region’s healthcare landscape.

The India market is gaining traction, fueled by the rising medical expenditure for eye care and the availability of innovative therapeutic regimens. The evolution of ophthalmic suspensions, antihistamines, and mast cell stabilizers is further accelerating growth in the region. For instance, in April 2024, Lupin Limited notified that it received the U.S FDA clearance for Loteprednol Etabonate, an ophthalmic suspension, 0.5%, to alleviate the symptoms of seasonal allergic conjunctivitis. Additionally, the push for accessible eye care is prompting firms to adopt allergic conjunctivitis therapies, making India a rapidly emerging player in the global market.